Sources:
Guglielmelli, P., & Calabresi, L. (2021). The MPL mutation. In International Review of Cell and Molecular Biology (Vol. 365).
Hoffman, R., et al., (2007). Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment. Biology of Blood and Marrow Transplantation, 13(64-72).
Kiladjian, J.J., et al., (2016). Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone. Leukemia, 30(4), 776–781.
Lasho, T. L., Finke, C. M., Hanson, C. A., Jimma, T., Knudson, R. A., Ketterling, R. P., Pardanani, A., & Tefferi, A. (2012). SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia, 26(5), 1135–1137. https://doi.org/10.1038/leu.2011.320
Masubuchi, N., et al., (2020). Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia, 34(2), 499–509.
Nangalia, J., et al., (2015). DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica, 100(11), 438-442.
Tefferi, A., et al., (2014). CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia, 28(7), 1472–1477.
Tefferi, A., et al., (2018). Revised cytogenetic risk stratification in primary myelofibrosis: Analysis based on 1002 informative patients. Leukemia, 32(5).
Vannucchi, A. M., et al., (2011). JAK2 allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2(1), 21-32.